Related by context. All words. (Click for frequent words.) 79 Relapsed Refractory 77 Previously Treated 76 Cutaneous T 74 Well Tolerated 74 Diffuse Large B 73 Previously Untreated 73 Elderly Patients 73 Chronic Hepatitis C 73 Patients Treated 73 Monotherapy 73 Castration Resistant Prostate Cancer 72 Antitumor Activity 72 Relapsed Refractory Multiple Myeloma 72 Refractory Hodgkin Lymphoma 72 Metastatic Colorectal Cancer 71 Patients Treated With 71 Improves Survival 71 Plus Ribavirin 71 Improves Outcomes 71 Newly Diagnosed Multiple Myeloma 71 Peginterferon Alfa 2a 71 Refractory Peripheral T 70 Adjuvant Therapy 70 Soft Tissue Sarcoma 70 Relapsing Multiple Sclerosis 70 Advanced Solid Tumors 70 Study Evaluating 70 Advanced Renal Cell 70 Oral Fingolimod 70 Advanced Melanoma 70 Relapsing Remitting Multiple Sclerosis 69 cell lymphoma CTCL 69 Phase III Trial 69 5 FU leucovorin 69 Adjuvant Treatment 69 Adjunctive Therapy 69 Renal Cell Carcinoma 69 Meets Primary Endpoint 69 Chronic Myeloid Leukemia 69 dasatinib Sprycel ® 69 Node Positive 68 dependent kinase inhibitor 68 Phase 2b Clinical Trial 68 Treatment Experienced 68 Anti Tumor Activity 68 stage IIIB 68 Cyclophosphamide 68 Relapsed Refractory Aggressive 68 Orally Active 68 Complicated Skin 68 Phase IIb Trial 68 R roscovitine CDK cyclin 68 Hormone Refractory Prostate Cancer 68 Hepatitis C Patients 68 leukemia CLL 68 Postmenopausal Women 68 Newly Diagnosed 68 Phase 2b Study 68 Adjuvant Chemotherapy 68 Patients Receiving 68 Cell Lymphoma 67 Advanced Ovarian Cancer 67 irinotecan containing 67 Is Well Tolerated 67 Treatment Naïve Patients 67 Infected Patients 67 Pooled Analysis 67 Fludarabine 67 Controlled Trial 67 Prolongs Survival 67 Bortezomib 67 Autologous Stem Cell Transplantation 67 Novel Oral 67 Metastatic Renal Cell Carcinoma 67 Preclinical Data 67 refractory chronic lymphocytic 67 Significantly Reduced 67 Clinical Trial Results 67 systemic anaplastic large 67 Improve Survival 67 Partial Onset Seizures 67 Survival Benefit 67 Solid Tumors 67 Anthracycline 66 II Clinical Trial 66 Androgen Deprivation Therapy 66 Severe Sepsis 66 Metastatic Prostate Cancer 66 Peginterferon 66 Peginterferon Alfa 2b 66 Patients Undergoing 66 Follicular Lymphoma 66 Radical Prostatectomy 66 Improved Survival 66 Advanced Prostate Cancer 66 imatinib Gleevec ® 66 Voreloxin 66 Trial Evaluating 66 Seliciclib CYC# 66 Statin Therapy 66 Complete Remission 66 Paraplatin ® 66 Completes Enrollment 66 Tolerability 66 Single Dose 66 Rheumatoid Arthritis Patients 66 Receives Orphan Drug Designation 66 Kidney Transplant Recipients 66 alfa 2a 66 Combination Treatment 66 Lenalidomide 66 Appears Safe 66 metastatic malignant 66 Advanced Colorectal Cancer 66 Drug Candidate 66 HER2 Positive Breast Cancer 66 TO AVOID PREGNANCY WHILE 66 Chronic Lymphocytic Leukemia 66 Mouse Model 66 Treatment Naive 66 Pegylated Liposomal Doxorubicin 66 small lymphocytic lymphoma 66 FEMALES SHOULD BE ADVISED 66 Phase IIa Clinical Trial 66 Treatment Naive Patients 66 Increased Risk 66 Unfractionated Heparin 66 Relapsed Multiple Myeloma 65 Nucleoside 65 Treatment Naive HIV 65 Capecitabine 65 Demonstrates Positive 65 Induces 65 Chemoradiation 65 Epratuzumab 65 Prognostic Significance 65 Clinical Trial Evaluating 65 Pivotal Study 65 Metastatic Melanoma 65 R lenalidomide 65 sunitinib Sutent ® 65 Spectrum Pharmaceuticals Announces 65 refractory cutaneous T 65 following fluoropyrimidine oxaliplatin 65 Significantly Reduces 65 Fluorouracil 65 Combination Therapy 65 Albuferon TM 65 Neoadjuvant 65 Humanized Anti 65 Phase IIb Clinical Trial 65 Liver Metastases 65 Hemodialysis Patients 65 cyclophosphamide doxorubicin vincristine 65 Randomized Double Blind 65 Phase 2b Trial 65 Patients Suffering 65 FOLFIRI 65 Investigational Agent 65 Versus Placebo 65 Anti Tumor 65 Statistically Significant 65 Demonstrated Significant 65 Heart Failure Patients 64 Placebo Controlled Trial 64 Inhibits 64 cyclophosphamide methotrexate 64 Epoetin Alfa 64 Carcinoma 64 stage IIIb IV 64 Leukemias 64 Myelofibrosis 64 SPRYCEL ® 64 Cardiovascular Events 64 acute peptic ulcer 64 interferon beta 1a infertility 64 Myelodysplastic Syndromes 64 Presents Preclinical Data 64 Prophylactic Treatment 64 Initiates Phase 64 PEGylated Fab fragment 64 Unresectable 64 Invasive Breast Cancer 64 Controlled Study 64 FOLFOX6 64 Treatment Resistant 64 Pharmacokinetics PK 64 Long Term Efficacy 64 Breast Cancer Patients 64 Predict Response 64 Hsp# Inhibitor 64 hydroxymethyl coenzyme 64 Chronic Hepatitis B 64 Randomized Double Blind Placebo 64 Decitabine 64 Irinotecan 64 Nilotinib 64 Shows Efficacy 64 Myeloma Patients 64 Subgroup Analysis 64 Pediatric Patients 64 Carboplatin Paclitaxel 64 PEGylated anti 64 Non Responders 64 Hematological Malignancies 64 Tumor Growth 64 Malignant Melanoma 64 Investigational Compound 64 Completes Patient Enrollment 63 Colorectal Cancer Patients 63 Pegylated 63 Progenitor Cells 63 Trastuzumab 63 cell carcinoma RCC 63 Randomized Controlled Trial 63 Sustained Virologic Response 63 Granted Orphan Drug 63 Bevacizumab 63 Demonstrates Significant 63 Dose Escalation Study 63 irinotecan doxorubicin oxaliplatin paclitaxel 63 Treatment Naïve 63 sunitinib Sutent 63 Stent Implantation 63 Critically Ill Patients 63 Induction Therapy 63 refractory NSCLC 63 Resistant Hypertension 63 Double Blind Placebo 63 Combination REOLYSIN R 63 Newly Diagnosed Chronic Myeloid 63 IN PATIENTS WITH 63 Brentuximab Vedotin SGN 63 Phase III Clinical Trial 63 Randomized Phase 63 Radiofrequency Ablation 63 Hormone Receptor Positive 63 Disease Progression 63 Meta Analysis 63 Non Hodgkin 63 Efficacious 63 Recurrent Ovarian Cancer 63 Philadelphia Chromosome Positive 63 Telaprevir VX 63 Initiate Phase III 63 Knee Osteoarthritis 63 Diabetic Patients 63 Investigational Drug 63 Metabolic Efficiency 63 Slow Progression 63 Randomized Phase II 63 Carcinomas 63 Treated Patients 63 Metastatic Breast Cancer 63 REVLIMID R 63 8mg/kg 63 Chronic Lymphocytic Leukemia CLL 63 Presents Positive 63 Targeted Therapy 63 rituximab refractory 63 Antitumor activity 63 Neuroendocrine Tumors 63 Novel Treatments 63 Kinase Inhibitor 63 T Cell Lymphoma 63 unresectable 63 Ranolazine 63 Pivotal Phase 63 Investigational Treatment 63 Lung Cancer Patients 63 hypertrichosis occurred 63 Ischemic Stroke 62 Gemcitabine 62 TNF Tumor Necrosis Factor 62 Protease Inhibitor 62 Localized Prostate Cancer 62 PRN FDA Approves 62 First Patient Dosed 62 Diabetic Nephropathy 62 DOXIL 62 Primary Hypercholesterolemia 62 Rituximab 62 Mantle Cell Lymphoma 62 Pharmacokinetic Study 62 ERBITUX cetuximab 62 Hepatitis C Genotype 62 cisplatin gemcitabine 62 erlotinib Tarceva ® 62 Low Dose 62 Novel Inhibitor 62 Anti TNF 62 relapsed refractory 62 Initiate Phase 62 Study Showed 62 Inhaled Corticosteroids 62 ST Segment Elevation 62 cetuximab Erbitux R 62 HER2 Positive 62 Significantly Improved 62 CVP cyclophosphamide vincristine 62 Multiple Myeloma Patients 62 Neoadjuvant Chemotherapy 62 Pegylated Interferon 62 adriamycin 62 Dialysis Patients 62 Dexamethasone 62 Toxicities 62 metastatic GIST 62 Endometrial Cancer 62 Perifosine KRX 62 Pivotal Phase III 62 Prostate Cancer Patients 62 Hypertensive Patients 62 Renal Impairment 62 Shows Promising 62 Myelodysplastic Syndrome MDS 62 Pivotal Trial 62 severe neutropenia 62 Phase 2a Trial 62 Subcutaneous 62 Tyrosine Kinase Inhibitor 62 relapsed follicular lymphoma 62 Breast Cancer Recurrence 62 Allogeneic 62 Naive Patients 62 Taxane 62 PNP inhibitor 62 Nebulized 62 previously untreated follicular 62 bevacizumab Avastin R 62 Ibritumomab Tiuxetan 62 Phase 2a Clinical Trial 62 Lupus Nephritis 62 Myelodysplastic Syndrome 62 Present Preclinical Data 62 q#h 62 ® lenalidomide 62 imatinib resistant 62 thalidomide Thalomid 62 Metastatic 62 Atypical Hemolytic Uremic Syndrome 62 Antiviral Activity 62 Brain Metastases 62 non splenectomized 62 Bone Metastases 62 leukemia AML 62 Initiate Clinical Trial 62 ribavirin Copegus ® 62 DOXIL ® 62 Study Demonstrates 62 Newly Diagnosed Patients 62 Patient Enrollment 62 nilotinib Tasigna ® 62 administered concomitantly 62 advanced metastatic renal 62 Phase III Trials 62 leukopenia pancytopenia thrombocytopenia 62 CYT# potent vascular disrupting 62 relapsed Acute Myeloid 62 Immune Responses 62 myelodysplastic myeloproliferative diseases 62 dacarbazine 62 receiving INTRON 61 HCV Protease Inhibitor 61 Asymptomatic 61 HDAC Inhibitor 61 Bare Metal Stents 61 Enoxaparin 61 Ofatumumab 61 dacarbazine DTIC 61 FUSILEV enhances 61 Randomized Clinical Trial 61 Dose Escalation 61 Lung Cancer Trial 61 4mg/kg 61 Phase III Pivotal Trial 61 Vincristine 61 Oral Formulation 61 Begins Dosing 61 Platinol ® 61 Initiates Clinical Trial 61 Lung Cancers 61 Xeloda ® 61 Peginterferon alfa 2b 61 tumors GIST 61 Fixed Dose 61 Blood Clots 61 Antigen Specific 61 ISTODAX ® 61 Randomized Study 61 Long Term Outcomes 61 Polymerase Inhibitor 61 Viral Load 61 Demonstrate Significant 61 Demonstrates Potent 61 PEG IFN 61 Demonstrates Potential 61 Acute Ischemic Stroke 61 Secondary Hyperparathyroidism 61 Antiangiogenic 61 Files IND 61 Seasonal Allergic Rhinitis 61 Proves Effective 61 Pulmonary Arterial Hypertension 61 essential thrombocythemia ET 61 Induction Chemotherapy 61 TNF Blockers 61 PEGINTRON TM 61 Novel Compound 61 metastatic renal cell carcinoma 61 Shows Promise 61 investigational oral inhibitor 61 cutaneous T 61 Preclinical Models 61 neutropenia dehydration dyspnea 61 carcinoma mCRC 61 Investigational Oral 61 Personalized Immunotherapy 61 J Am Acad 61 Azacitidine 61 Bosutinib 61 severe oral mucositis 61 class anticancer quinolone 61 ribavirin therapy 61 nonmetastatic 61 Cell Lung Cancer 61 Dose Finding 61 Abciximab 61 Pralatrexate 61 estramustine 61 Renal Function 61 Increases Risk 61 Plaque Psoriasis 61 lenalidomide Revlimid R 61 Infliximab 61 Posaconazole 61 purpura ITP 61 recurrent glioblastoma multiforme 61 Chemotherapy Improves 61 Preclinical Study 61 Cognitive Impairment 61 Omacetaxine 61 Leukemia AML 61 Mylan Receives Approval 61 Romidepsin 61 Acute Myeloid Leukemia AML 61 First Patient Enrolled 61 Advanced Pancreatic Cancer 61 Metastases 61 evaluating picoplatin 61 Significantly Improves 61 monoclonal antibody IgG1 Mab 61 Based Regimens 61 Sustained Efficacy 61 Vaccine Adjuvant 61 NDA Submission 61 tumor lysis syndrome 61 ACE Inhibitors 60 JAK2 Inhibitor 60 Metastatic Pancreatic Cancer 60 relapsed refractory multiple myeloma 60 situ CIS 60 Abiraterone Acetate 60 bone marrow reticulin deposition 60 Venous Thromboembolism 60 Hepatocellular 60 Chronic Renal Failure 60 Heterozygous Familial Hypercholesterolemia 60 Medoxomil 60 Mg Uk 60 Multiple Myeloma MM 60 Effectively Treats 60 refractory peripheral T 60 plus prednisone 60 Sirolimus Eluting Stent 60 plus prednisone prednisolone 60 Ph + acute lymphoblastic 60 metastatic castration resistant 60 Oncolytic Reovirus 60 Glufosfamide 60 arthritis PsA 60 docetaxel Injection Concentrate 60 MEK Inhibitor 60 Percutaneous Coronary Intervention 60 Malignant Glioma 60 familial amyloidotic polyneuropathy FAP 60 Tumor Progression 60 Blood Pressure Lowering 60 Orthop Surg 60 Effective Than 60 Myeloid 60 Randomized Double blind 60 Chemotherapy Induced 60 Genes Predict 60 mGluR5 negative 60 Sipuleucel T 60 ST Elevation Myocardial 60 Disease Modifying 60 Orthostatic Hypotension 60 FOLFOX6 chemotherapy regimen 60 recurrent NSCLC 60 vinorelbine 60 Potent Anti 60 relapsed multiple myeloma 60 ribavirin RBV 60 Factor Receptor 60 Combination Clinical Trial 60 Tiotropium 60 Shows Statistically Significant 60 Chronic Myelogenous Leukemia 60 Breast Cancers 60 IND Application 60 Myocardial Infarction Study 60 Lymphomas 60 Enrolls First 60 resistant hormone refractory 60 Adefovir 60 R Saizen R 60 Paclitaxel Carboplatin 60 5 fluorouracil leucovorin 60 Interferon Beta 60 Emerging Therapies 60 carboplatin paclitaxel 60 Stent Restenosis 60 Balloon Angioplasty 60 unresectable stage 60 Beneficial Effects 60 5 Fluorouracil 60 Platelet Inhibition 60 Fulvestrant 60 BCG refractory carcinoma 60 Meet Primary Endpoint 60 Zoledronic Acid 60 Picoplatin Efficacy After 60 Erlotinib 60 Acute Myocardial Infarction 60 Gene Mutation 60 gastrointestinal stromal tumor GIST 60 Randomized Placebo Controlled Trial 60 Vascular Disrupting Agent 60 NICE Recommends 60 Gastric Cancer 60 Hypercholesterolemia 60 Postmenopausal Osteoporosis 60 anthracycline taxane 60 Recombinant Human 60 Inadequately Controlled 60 EGFR TKI 60 FDA Okays 60 Multicenter Study 60 Prospective Randomized Trial 60 Receptor Antagonist 60 TRAIL R1 60 evaluating tivozanib 60 Natalizumab 60 Ovarian Cancer Patients 60 CHOP chemotherapy 60 Doxil ® 60 Cisplatin 60 Chronic Sinusitis 60 Pemetrexed 60 Pegloticase 60 Aurora Kinase 60 Achieves Primary Endpoint 60 Immunomodulatory 60 VELCADE melphalan 60 Commonly Used 60 Transdermal Patch 60 docetaxel Taxotere ® 60 Increased Mortality 60 Stage IIIB IV 60 B Cell Lymphoma 60 Squamous 60 plus dexamethasone 60 Hodgkin lymphoma NHL 60 trastuzumab Herceptin R 60 Reduces Risk 60 Unstable Angina 60 Placebo Controlled 60 HCV Genotype 60 Cholesterol Lowering Drug 60 intravesical infusion therapy 59 fallopian tube cancers 59 ritonavir boosted 59 Clinical Outcome 59 Chemotherapeutic Agents 59 Adalimumab 59 fallopian tube carcinoma 59 refractory follicular 59 Mouse Models 59 Oral Anticoagulant 59 Placebo Controlled Study 59 Lowers Risk 59 Teva Provides Update 59 Xenografts 59 forodesine purine nucleoside phosphorylase 59 See CONTRAINDICATIONS 59 fluorouracil leucovorin 59 novel emulsion formulation 59 Adenoma 59 Camptosar ® irinotecan 59 ovarian esophageal 59 Sirolimus Eluting 59 Suppresses 59 Insulin Resistance 59 lymphoma CTCL 59 D aspartate NMDA receptor 59 hypereosinophilic syndrome 59 Insulin Glargine 59 Initiates Phase III 59 Hyperlipidemia 59 candesartan cilexetil 59 EGFR expressing mCRC 59 pan histone deacetylase 59 dexamethasone Decadron 59 NCCN Updates 59 hypothyroidism hyperglycemia hypotension arrhythmihemorrhagic colitis development 59 pralatrexate injection folate analogue 59 Epothilone D 59 Prophylaxis 59 Anticancer Drugs 59 mg q#h 59 imatinib mesylate 59 Left Ventricular 59 Gemzar ® 59 Etanercept 59 VEGFR2 inhibitor 59 unresectable locally advanced 59 Vildagliptin 59 REVLIMID ® 59 CHOP cyclophosphamide doxorubicin vincristine 59 potentially hepatotoxic 59 Kidney Transplants 59 atypical Hemolytic Uremic Syndrome 59 FDA Accepts 59 Clinical Efficacy 59 unresectable Stage III 59 chronic immune thrombocytopenic 59 dextromethorphan quinidine 59 Hepatocellular Carcinoma 59 Palifosfamide 59 Drug Resistant 59 Adenocarcinoma 59 mitoxantrone plus 59 Partial Seizures 59 unresectable recurrent 59 FASLODEX 59 Randomized Phase III 59 Submits NDA 59 Initiates Phase II 59 Multicenter Randomized Double 59 Vidaza ® 59 Chronic Bronchitis 59 Tumor Cell 59 Kit CD# positive 59 RNAi Therapeutic 59 Folfox 59 Mitral Regurgitation 59 ara C 59 primary hypercholesterolemia 59 Endothelial Cells 59 EGFR HER2 59 Bladder Cancer 59 Pancreatic Adenocarcinoma 59 Cell Transplants 59 Ovitrelle R Serostim 59 rheumatoid arthritis RA psoriatic 59 Viral Suppression 59 Monoclonal Antibody 59 Severe Asthma 59 pegylated liposomal doxorubicin 59 alfa 2b 59 complement inhibitor eculizumab 59 Improve Outcomes 59 Serious Infections 59 cancer mCRC 59 alpha 2a 59 Chronic Insomnia 59 Dose Ranging Study 59 Carotid Stenting 59 TAXOTERE R 59 Gene Linked 59 sorafenib Nexavar 59 mapatumumab 59 Aflibercept 59 Dasatinib 59 Disease Severity 59 metastatic colorectal carcinoma 59 Bosentan 59 Diabetic Neuropathic Pain 59 Progressive Multifocal Leukoencephalopathy 59 Safety Tolerability 59 follicular CD# positive 59 Breast Cancer Treatment 59 sodium glucose cotransporter 59 Rectal Cancer 59 Treatment Reduces 59 interferon alfa 2a 59 Solid Tumors criteria 59 Slows Progression 59 COPEGUS R 59 Hedgehog Pathway 59 Osteoporosis Drugs 59 HBeAg positive 59 completely resected 59 Overactive Bladder 59 CYP#A# CYP#D# 59 Oral Mucositis 59 BARACLUDE ® 59 Squamous Cell Carcinoma 59 Skeletal Muscle 59 Atypical Antipsychotics 59 Chronic HCV 59 cutaneous T cell 59 valsartan amlodipine 59 topoisomerase II inhibitor 59 Liver Cancer 59 Colorectal Adenomas 59 Taxotere ® 59 Enlarged Prostate 59 Median PFS 59 lymphoid blast 59 Gliadel R 59 pegylated interferon alfa 2a 59 #mg BID [003] 59 Initiates Clinical 59 Phase Ib Clinical Trial 59 nucleoside analog 59 Randomized Trials 59 Kidney Function 59 fluorouracil 59 Melphalan 59 receptor tyrosine kinase inhibitor 58 Desvenlafaxine Succinate 58 advanced hepatocellular carcinoma 58 Tyrosine Kinase Inhibitors 58 AVASTIN 58 Anticancer Activity 58 Receives Orphan Drug 58 Advanced Gastric Cancer 58 Carboplatin 58 Panic Disorder 58 subependymal giant cell 58 Prospective Randomized 58 gemcitabine Gemzar 58 Initiates Enrollment 58 refractory multiple myeloma 58 Exacerbation 58 metastatic castrate resistant 58 Inflammatory Pain 58 Treating Chronic 58 keloid scarring 58 Certolizumab 58 LENALIDOMIDE 58 Chronic Heart Failure 58 efavirenz EFV 58 Higher Doses 58 Therapy Improves 58 Radiofrequency Ablation RFA 58 PEGylated interferon beta 1a 58 FDA Approves 58 HER2 positive metastatic breast 58 Thromboembolism 58 2 methoxyestradiol 58 R minocycline HCl 58 primary peritoneal 58 Cognitive Decline 58 Data Suggest 58 Diuretic 58 Acute Myeloid Leukemia 58 cetuximab Erbitux ® 58 Fludara ® 58 gefitinib Iressa 58 Predict Risk 58 Tipranavir 58 Mg Usa 58 Antiviral Therapy 58 PKC# 58 CYPHER R Sirolimus Eluting 58 Minimally Invasive Treatment 58 Randomized Controlled 58 Amrubicin 58 Radioimmunotherapy 58 influenza BCX# purine nucleoside 58 unfractionated heparin UFH 58 Successfully Treated 58 brand ciclesonide HFA 58 bevacizumab Avastin ® 58 demonstrated antitumor activity 58 B Cell Malignancies 58 HGS ETR1 58 Depressive Symptoms 58 myocardial infarction ventricular fibrillation 58 cyclophosphamide doxorubicin 58 Cardiovascular Outcomes 58 refractory acute myeloid 58 Acute Coronary Syndromes 58 alpha folate receptor 58 Reduced Incidence 58 Vitro Activity 58 Paclitaxel Eluting 58 Eluting Stent 58 Non Inferiority 58 receiving highly emetogenic 58 Pegasys ® 58 relapsed acute myelogenous 58 Renal Artery 58 Acute Exacerbations 58 6 mercaptopurine 58 RISKS UNCERTAINTIES AND ASSUMPTIONS 58 nab paclitaxel 58 HGS ETR2 58 Cancer Patients Treated 58 Primary Endpoint 58 Drug Shows Promise 58 cisplatin carboplatin 58 Demonstrates Efficacy 58 Sustained Reduction 58 mg BID 58 FOLFOX4 58 Enzyme Replacement Therapy 58 alkylating agent 58 oral nucleoside analogue 58 triggers apoptosis programmed 58 azacitidine 58 fludarabine 58 transitional cell carcinoma 58 Hemolysis 58 moderate hepatic impairment 58 CDK cyclin dependent 58 Kinase Inhibitors 58 Ischemic 58 humanized interleukin 6 58 Chemotherapy Regimen 58 Docetaxel 58 Cell Lymphoma CTCL 58 Double Blind Randomized 58 Uterine Fibroid Embolization 58 Significant Improvement 58 Mayo Clinic Study Finds 58 R# #mg BID 58 Blinatumomab 58 Navelbine ® 58 Sapacitabine 58 Cell Non Hodgkin 58 taxane chemotherapy administered 58 Epidermal Growth Factor Receptor 58 Commonly Prescribed 58 Ozarelix 58 Tezampanel 58 FOLFOX 58 Treatment Regimen 58 hormone refractory metastatic prostate 58 Antitumor 58 Navelbine 58 Stomach Cancer 58 oropharyngeal candidiasis OPC 58 Stereotactic Body Radiation Therapy 58 Sangamo BioSciences Announces 58 Prostate Biopsy 58 Prostatectomy 58 relapsed MM 58 Ribavirin 58 Aggressive Prostate Cancer 58 Topline Results 58 interferon alfa 2b 58 Flu Cy 58 erythematosus 58 Free Survival PFS 58 gemcitabine carboplatin 58 Atypical Antipsychotic 58 Isavuconazole 58 refractory indolent non 58 Tumor Necrosis Factor 58 Pharmacokinetics 58 Adjunctive 58 Receptor Antagonists 58 Node Negative 58 Attenuates 58 Thrombotic 58 Valopicitabine NM# 58 Synta Announces 58 Bivalirudin 58 alefacept 58 relapsed refractory aggressive 58 Lanthanum Carbonate 58 Cystectomy 58 colesevelam HCl 58 papillary renal cell carcinoma 58 Tiuxetan 58 Diabetic Neuropathy 58 Darbepoetin Alfa 58 plus gemcitabine 58 Stem Cell Transplants 58 Previously Untreated Multiple Myeloma 58 mRCC 58 Shoulder Prosthesis 58 acute GvHD 58 voriconazole 58 Commence Phase 58 Clostridium difficile Infection 58 Chronic Myeloid Leukemia CML 58 Fungal Infections 58 Patency 58 Benign Prostatic Hyperplasia 58 Induces Apoptosis 58 R bendamustine hydrochloride 58 Combo Therapy 58 JAK Inhibitor 58 Statistical Significance 58 LHRH receptor positive 57 Nerve Pain 57 Etiology 57 Dual Antiplatelet Therapy 57 Receives Fast Track 57 NMIBC 57 Randomised Trial 57 5-FU/LV 57 refractory follicular lymphoma 57 Laboratory pH Electrodes 57 Amgen Neulasta R 57 Vinorelbine 57 Glycemic Control 57 Mycophenolate Mofetil 57 xenograft models 57 CML CP 57 Initiates Phase 2b 57 dual endothelin receptor antagonist 57 Vertebral Compression Fractures 57 Occlusive Disease 57 relapsed acute lymphoblastic 57 FDA Approves Drug 57 Shows Promise Against 57 Long Term Survival 57 Known hypersensitivity 57 Premenopausal Women 57 paclitaxel Taxol R 57 Vicriviroc 57 See CLINICAL PHARMACOLOGY 57 Interferon Alfa 57 idarubicin 57 Renal Insufficiency 57 Proc Am Soc 57 Pre Cancerous 57 Lupus Drug 57 Receives Positive Opinion 57 TTF Therapy 57 Study Shows Promise 57 Alemtuzumab 57 melphalan prednisone 57 Multicenter Trial 57 See WARNINGS 57 Fracture Risk 57 ceftazidime 57 Papillary 57 FOLOTYN ® 57 metastatic carcinoma 57 Metastatic Disease 57 indolent follicular non 57 Child Adolesc Psychiatry 57 PEGASYS ® 57 prostate cancer HRPC 57 Recurrent Glioblastoma 57 leukemia ALL 57 Oral Calcitonin 57 Protease Inhibitors 57 leukemia APL 57 Intracranial Aneurysms 57 Blind Placebo Controlled Trial 57 plus dacarbazine 57 allosteric modulator NAM 57 InNexus Biotechnology Announces 57 CCX# B 57 temsirolimus Torisel 57 Sevelamer 57 MGd 57 gastrointestinal stromal tumor 57 Gout Drug 57 Hematological Cancers 57 Imatinib 57 follicular NHL 57 Prognostic Factors 57 #mg/m# [001] 57 plus DOXIL 57 Copegus ribavirin 57 Hodgkin lymphoma HL 57 hepatitis B reactivation 57 induced macular edema 57 Platinol ® cisplatin 57 Etoposide 57 virus HCV protease inhibitor 57 Camptosar ® 57 superficial bladder cancer 57 non myeloid malignancies 57 Imatinib mesylate 57 Idiopathic Pulmonary Fibrosis 57 xanthine oxidase inhibitor 57 Tolvaptan 57 CYP#A# substrate